PEAnut Anaphylaxis Predictors
NCT02424136 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 40
Last updated 2020-01-22
Summary
Peanut allergy can be life-threatening. Current diagnostic techniques for peanut allergy have high sensitivity, but not high specificity. This clinical trial will test the validity of a novel blood biomarker (compared with current testing) as a diagnostic predictor of anaphylaxis to peanut.
Conditions
- Peanut Hypersensitivity
- Anaphylaxis
Interventions
- OTHER
-
Questionnaire
5 minute questionnaire focused on symptoms of allergic disease
- OTHER
-
Peanut Skin prick test
Skin prick testing with peanut antigen, according to ASCIA Skin Prick testing manual
- OTHER
-
Fraction of exhaled nitric oxide
Measurement of exhaled nitric oxide, according to American Thoracic Society/ European Thoracic Society (ATS/ERS) standardised procedures (Not required for those age less than 6 years).
- OTHER
-
Spirometry
Measurement of lung flows/volumes, according to ATS/ERS standardised procedures (Not required for those age less than 6 years).
- OTHER
-
Serum Peanut and Ara h2 specific immunoglobulin E
Peanut and Ara h2 specific IgE antibodies
- OTHER
-
Collection of blood biomarker
Correlation of blood biomarker levels in patients with successful or unsuccessful peanut food challenge
- OTHER
-
Peanut food challenge
Open label peanut challenge conducted according to ASCIA's peanut challenge protocol and PRACTALL consensus report
Sponsors & Collaborators
-
Hunter Medical Research Institute, Australia
collaborator UNKNOWN -
University of Newcastle, Australia
collaborator OTHER -
Thrasher Research Fund
collaborator OTHER -
Hunter Childrens Research Foundation, Australia
collaborator UNKNOWN -
Aerocrine AB
collaborator INDUSTRY -
John Hunter Children's Hospital
lead OTHER
Principal Investigators
-
Joerg Mattes, MD · John Hunter Children's Hospital, Australia
Study Design
- Allocation
- NA
- Purpose
- DIAGNOSTIC
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 2 Years
- Max Age
- 17 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2015-07-22
- Primary Completion
- 2018-08-28
- Completion
- 2019-12-31
Countries
- Australia
Study Locations
More Related Trials
-
1-hour Premedication for Allergy Goal in Emergency: PAGE-1 Study
NCT07268248 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Anakinra Pilot 2 - A Study to Optimise Dose and Route of Administration of Anakinra in Preterm Infants
NCT07254000 ·Status: RECRUITING ·Phase: PHASE2
-
What is the Allergy Follow-up for Children After Anaphylactic Reaction? AFCAR : Allergy Follow-up for Children After Anaphylactic Reaction
NCT03942692 ·Status: COMPLETED
-
Anakinra for Preterm Infants Pilot
NCT05280340 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
Validation of the HYPONUT Product
NCT03849079 ·Status: TERMINATED ·Phase: NA
-
Pediatric Patients Aged 1 to 6 Years With APDS
NCT05693129 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Prednisolone Trial in Children Younger Than 4 Years
NCT03141970 ·Status: COMPLETED ·Phase: PHASE3
-
Role of Neutrophil Activation in Anaphylaxis to Neuro-Muscular Blocking Agents
NCT01637220 ·Status: COMPLETED
-
PK/PD Study of IN-001 Sublingual Spray in Healthy Adults
NCT07210320 ·Status: COMPLETED ·Phase: PHASE1
-
Epidemiology and Management of Pediatric Anaphylaxis and Allergy in the Pediatric Emergency Department of Montpellier
NCT05112367 ·Status: UNKNOWN
-
Pediatric Prehospital Airway Resuscitation Trial
NCT06364280 ·Status: SUSPENDED ·Phase: NA
-
Clinical Trial Corticoids For Empyema And Pleural Effusion In Children
NCT01261546 ·Status: COMPLETED ·Phase: PHASE2
-
Pediatric Patients Aged 4 to 11 Years With APDS
NCT05438407 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Allergy to Neuromuscular Blocking Agents and Pholcodine Exposure
NCT02250729 ·Status: UNKNOWN ·Phase: NA
-
Study of Inhaled DMC-IH1 and Intramuscular (EpiPen®) Epinephrine in Healthy Male and Female Participants.
NCT06013150 ·Status: COMPLETED ·Phase: PHASE1
-
Study of the Safety and Tolerability of HPN-100 Compared to Sodium Phenylbutyrate in Children With Urea Cycle Disorders
NCT00947544 ·Status: COMPLETED ·Phase: PHASE2
-
Effects and Safety of Infusion of Low-Doses of Methylprednisolone in Early ALI and ARDS in Children
NCT01757899 ·Status: WITHDRAWN ·Phase: PHASE2
-
Pharmacokinetics of Intramuscular Adrenaline in Food--Allergic Teenagers
NCT03366298 ·Status: COMPLETED ·Phase: PHASE4
-
Association of Beta-2 Adrenergic Agonist and Corticosteroid Injection in the Treatment of Lipomas
NCT00624416 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Timing of Initiation of Parenteral Nutrition for Critically Ill Children
NCT04693143 ·Status: UNKNOWN ·Phase: NA
-
Clinical Assessment of Pharmacokinetics, Efficacy, and Safety of 10% IVIg in Pediatric PID Patients (KIDCARES10)
NCT04944979 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Intravenous Heparin as an Adjunct for the Treatment of Anaphylactic Reactions in an Emergency Department
NCT00657228 ·Status: WITHDRAWN ·Phase: NA
-
A Study of SmartFlow Magnetic Resonance (MR) Compatible Ventricular Cannula for Administering Eladocagene Exuparvovec to Pediatric Participants
NCT04903288 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Safety and Efficacy Study of Acthar in Subjects With ARDS
NCT02113735 ·Status: WITHDRAWN ·Phase: PHASE2
-
Diagnosis and Allergen Identification of Perioperative Anaphylaxis
NCT06793163 ·Status: RECRUITING